Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma

Por Hong, David S., Kurzrock, Razelle, Falchook, Gerald S., Andresen, Corina, Kwak, Jennifer, Ren, Min, Xu, Lucy, George, Goldy C., Kim, Kevin B., Nguyen, Ly M., O'Brien, James P., Nemunaitis, John
Publicado no Oncotarget (2015)

Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma

Por Hong, David S., Kurzrock, Razelle, Wheler, Jennifer J., Naing, Aung, Falchook, Gerald S., Fu, Siqing, Kim, Kevin B., Davies, Michael A., Nguyen, Ly M., George, Goldy C., Xu, Lucy, Shumaker, Robert, Ren, Min, Mink, Jennifer, Bedell, Cynthia, Andresen, Corina, Sachdev, Pallavi, O'Brien, James P., Nemunaitis, John
Publicado no Clin Cancer Res (2015)

A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine‐refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment

Por Cabanillas, Maria E., Schlumberger, Martin, Jarzab, Barbara, Martins, Renato G., Pacini, Furio, Robinson, Bruce, McCaffrey, Judith C., Shah, Manisha H., Bodenner, Donald L., Topliss, Duncan, Andresen, Corina, O'Brien, James P., Ren, Min, Funahashi, Yasuhiro, Allison, Roger, Elisei, Rossella, Newbold, Kate, Licitra, Lisa F., Sherman, Steven I., Ball, Douglas W.
Publicado no Cancer (2015)

Environment impacts the metabolic dependencies of Ras-driven non-small cell lung cancer

Por Davidson, Shawn M., Papagiannakopoulos, Thales, Olenchock, Benjamin A., Heyman, Julia E., Keibler, Mark A., Luengo, Alba, Bauer, Matthew R., Jha, Abhishek K., O’Brien, James P., Pierce, Kerry A., Gui, Dan Y., Sullivan, Lucas B., Wasylenko, Thomas M., Subbaraj, Lakshmipriya, Chin, Christopher R., Stephanopolous, Gregory, Mott, Bryan T., Jacks, Tyler, Clish, Clary B., Vander Heiden, Matthew G.
Publicado no Cell Metab (2016)